By Jim Tate – Several weeks ago I wrote a post entitled “MIPS and Medicare Part B Drugs – Waiting for the Other Shoe to Drop”. Late last week the other shoe hit the floor with the release of the Final Rule.
Read More
By Jim Tate – “Everybody talks about the weather, but nobody does anything about it”. I’m pretty sure Mark Twain said that. We might as well say “Everybody talks about MIPS, but nobody does anything about it”. Well, hardly anybody.
By Jim Tate – We are whiling away the time today on a visit to the piedmont of North Carolina. Even though it is October it feels like the dog days of August. Humidity off the charts and I don’t even want to look at the temperature. What’s a poor boy to do?
By Jim Tate – The MACRA/MIPS program is complex enough without having to decide what is real and what is not. I recently wrote a post entitled “Fake News – MIPS Style” and in the past week I have come across additional examples of misleading information that only serves to muddy the waters.
By Jim Tate – I sure hear a lot about fake news these days. In the world of politics, we hear a constant chant: “This is fake, that is fake, everything is fake”. I guess it is in the eye of the beholder as to what is true. There is the whole truth, the partial truth, misstatements of fact and downright Pinocchio lies.
By Jim Tate – There is less than two weeks left on the clock. October 2nd is coming fast and brings the beginning of the last 90-day MIPS performance period for 2017. If plans have not already been made then this week is the last opportunity.
By Jim Tate – Last week I documented yet another reason that the achievement of a high MIPS score should be Priority One for Eligible Clinicians. 2017 has been defined as the “Transition Year” for MACRA/MIPS and minimum standards have been put in place to allow minimal effort to avoid 2019 Part B adjustments.
By Jim Tate – We have reflected in earlier posts the critical importance of achieving a high MIPS score. Reimbursment, practice value, and professional reputation are all directly impacted by a MIPS score. Here is yet another collateral impact of a MIPS score: the ability to obtain and maintain a loan.
By Jim Tate – My recent post (The Open Secret of Health Information Technology – The Emperor Has No Clothes) lamented the fact that it is often extremely difficult to pry critical Clinical Quality files (QRDA-I and QRDA-III) out of an EHR. Well, it is time to name names, or at least one name.